Logo
x

Search category

Subscribe Now

foghorn therapeutics

Foghorn Therapeutics Reports Discontinuation of P-I Clinical Trial for FHD-286 in Metastatic Uveal Melanoma (mUM)

Foghorn Therapeutics Reports Discontinuation of P-I Clinical Trial for FHD-286 in Metastatic Uveal Melanoma (mUM)

  • June 29, 2023
Image

Incisive News in 3 Shots.

Contact Us

Our Information

Follow Us

Copyright © 2024 PharmaShots - All Rights Reserved.